Cosmo Pharmaceuticals NV (COPN) EUR0.26

Sell:58.10 CHFBuy:60.30 CHFNo change

Prices delayed by at least 15 minutes
Sell:58.10 CHF
Buy:60.30 CHF
Change:No change
Deal now
Prices delayed by at least 15 minutes
Sell:58.10 CHF
Buy:60.30 CHF
Change:No change
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Cosmo Pharmaceuticals N.V. is a pharmaceutical company. The Company is focused on gastrointestinal (GI) diseases, dermatology, and healthtech. Its development pipeline includes Distal Ulcerative Colitis, Bile Acid Diarrhea, Solid Tumors, and AI Augmented Endoscopy. The Company's developed products include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, which is used for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, which is a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo, which is used for the treatment of travelers’ diarrhea (TD); Methylene Blue MMX, which is a diagnostic drug to improve precancerous and cancerous lesion detection during colonoscopy, and Winlevi, which is used for the treatment of acne. It also develops medical devices to assist with clinical decision-making.

Key people

Giovanni Di Napoli
Chief Executive Officer, Executive Director, Member of the Management Board
Svetlana Sigalova
Chief Financial Officer, Member of the Management Board
Marco Lecchi
Chief Operating Officer, Member of the Management Board
Niall Donnelly
Executive Vice President - Corporate Governance & Chief Sustainability Officer, Executive Director, Member of the Management Board
Giulio Evangelisti
Senior Vice President - Manufacturing, Service and Security at Cosmo Intelligent Medical Devices, Member of the Management Board
Mara Gerloni
Senior Vice President - Preclinical Operations, Member of the Management Board
Luigi Longo
Chief Scientific Officer, Member of the Management Board
Andrea Cherubini
Chief AI Officer, Member of the Management Board
Egle Gedrimaite
Member of the Management Board, Head of Global Business Development
Diana Harbort
President - Dermatology Division, Member of the Management Board
Alessandro Della Cha
Non-Executive Chairman of the Board
Mauro Severino Ajani
Non-Executive Director
John Odea
Non-Executive Director
Silvana Perretta
Non-Executive Director
Maria Grazia Roncarolo
Non-Executive Director
Click to see more

Key facts

  • EPIC
    COPN
  • Location
    Ireland
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    NL0011832936
  • Market cap
    CHF 1.04bn
  • Employees
    322
  • Shares in issue
    17.54m
  • Exchange
    SIX Swiss Exchange
  • Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.